MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

Home・Akcijų sąrašas・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

4.36 -0.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.3

Max

4.44

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-12M -27M
Pardavimai	-5.3M 663K
P/E Sektoriaus vid.	22.5 66.418
Pelno marža	-3,998.492
Darbuotojai	69
EBITDA	-13M -27M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+211.39% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-193M 951M
Ankstesnė atidarymo kaina	4.59
Ankstesnė uždarymo kaina	4.36

Naujienos nuotaikos

By Acuity

50%

154 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

0.7658 / N/A Palaikymas ir pasipriešinimas

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-13 23:25; UTC

Svarbiausios naujienos

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

2026-04-13 22:45; UTC

Svarbiausios naujienos

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

2026-04-13 18:03; UTC

Uždarbis

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

2026-04-13 23:58; UTC

Uždarbis

Review & Preview: Earnings Time -- Barrons.com

2026-04-13 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

2026-04-13 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher Amid Dollar Weakness -- Market Talk

2026-04-13 23:20; UTC

Rinkos pokalbiai

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

2026-04-13 23:01; UTC

Uždarbis

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

2026-04-13 23:01; UTC

Uždarbis

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

2026-04-13 23:01; UTC

Uždarbis

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

2026-04-13 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

2026-04-13 21:26; UTC

Svarbiausios naujienos

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

2026-04-13 21:23; UTC

Uždarbis

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

2026-04-13 21:16; UTC

Uždarbis

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

2026-04-13 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-13 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-04-13 20:34; UTC

Uždarbis

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

2026-04-13 20:34; UTC

Uždarbis

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

2026-04-13 20:34; UTC

Uždarbis

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

2026-04-13 19:59; UTC

Rinkos pokalbiai

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

2026-04-13 19:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

2026-04-13 19:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Correction to Precious Metals Market Talk on April 9

2026-04-13 19:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

2026-04-13 18:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

2026-04-13 18:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

2026-04-13 18:43; UTC

Rinkos pokalbiai

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

211.39% į viršų

12 mėnesių prognozė

Vidutinis 13.67 USD 211.39%

Aukščiausias 17 USD

Žemiausias 11 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.7658 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

154 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.